Christopher N. Garabedian

Chris Garabedian is a Senior Advisor at the Boston Consulting Group. Previously, Chris served as the President and Chief Executive Officer of Sarepta Therapeutics from January 2011-March 2015 and as a member of Sarepta's board of directors from June 2010-March 2015. He is currently involved in the formation and co-founding of several early-stage biopharma companies.

Chris served as Vice President of Corporate Strategy for Celgene from 2007 to December 2010 where he was responsible for strategic planning, M&A, portfolio review and other strategic initiatives. Prior to Celgene, Chris worked at Gilead Sciences, Inc., from 1997 to 2005 where he served in a number of global leadership roles, including as Vice President of Corporate Development, Vice President of Marketing, and Vice President of Medical Affairs. While at Gilead Sciences, Chris's responsibilities ranged from managing corporate development initiatives, including portfolio review and strategic planning, M&A/business development, and leading four global product launches. Chris also held various commercial development positions at COR Therapeutics, Inc. from 1998 to 1999 and at Abbott Laboratories from 1994 to 1997. He started his biopharmaceutical career as a consultant with Migliara/Kaplan Associates from 1991 to 1994.

Chris is a frequent speaker across a variety of topics at industry conferences. He also serves as a Senior Advisor to the Boston Consulting Group, as a member of the MassBio Board of Directors, as a member of faculty of the GLG Institute, and as a member of the Board of Advisors for the Keck Graduate Institute.